CTC Counts May Help Predict mCRPC Patient Survival

Share this content:

Circulating tumor cell (CTC) enumeration (CELLSEARCH), along with measuring lactate dehydrogenase (LDH) as part of a composite biomarker panel, may be a good surrogate for survival in patients with metastatic castration-resistant prostate cancer (mCRPC).

John Schieszer has the latest on the story in today in today's Medical Minute.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters